CTI BioPharma (NASDAQ:CTIC) : During the past 4 weeks, traders have been relatively bearish on CTI BioPharma (NASDAQ:CTIC), hence the stock is down -19.8% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.55% relative to the S&P 500. The 4-week change in the price of the stock is -18.51% and the stock has fallen -2.32% in the past 1 week.
The company shares have dropped -82.05% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $1.99 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.41 and the 200 Day Moving Average price is recorded at $0.65.
The stock has recorded a 20-day Moving Average of 8.64% and the 50-Day Moving Average is 17.76%.
CTI BioPharma (NASDAQ:CTIC): On Fridays trading session , Opening price of the stock was $0.3523 with an intraday high of $0.3871. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.35. However, the stock managed to close at $0.3501, a loss of 3.66% for the day. On the previous day, the stock had closed at $0.3634. The total traded volume of the day was 1,860,984 shares.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President and CEO) of Cti Biopharma Corp, Bianco James A had sold 10,000 shares worth of $3,700 in a transaction dated June 24, 2016. In this transaction, 10,000 shares were sold at $0.37 per share.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.